A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Escalation Study to Assess the Safety and Efficacy of SL-1002 Injectable for Treatment of Knee Pain Associated with Osteoarthritis

Date Added
January 24th, 2023
PRO Number
Ameet Nagpal

List of Studies

Arthritis, Pain

The purpose of this study is to assess the safety and efficacy of the SL-1002 injectable formulation, compared to placebo, for the treatment of knee pain associated with osteoarthritis. The study will be conducted in two parts referred to as Phase A and Phase B. In Phase A of the study, there will be a total of 3 dosing groups of subjects. Phase B of the study will enroll a single group of subjects. This study will last approximately 26 weeks, which includes a screening period that includes 2 visits. After the first two screening visits and the study drug treatment visit (Day 0), the subject will be required to return to the study site for 7 additional study visits at approximately 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, and 6 months after the study drug treatment is administered on Day 0.

Recruitment Contact
Lisa Mock

-- OR --